Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865619 | 0.88 | CCR2 (0.41) | MAPTLMNACCR2TSHRL3MBTL1 | |
| SCHEMBL5865511 | 0.88 | L3MBTL1 (0.53) | SMN1; SMN2KMT2ATSHRL3MBTL1CYP3A4 | |
| SCHEMBL5865566 | 0.87 | MAPT (0.39) | MAPTLMNASMN1; SMN2KMT2ACCR2 | |
| SCHEMBL5865698 | 0.84 | CCR2 (0.39) | KMT2ACCR2TSHRL3MBTL1CYP3A4 | |
| SCHEMBL5865494 | 0.79 | TSHR (0.50) | SMN1; SMN2KMT2ACCR2TSHRL3MBTL1 | |
| SCHEMBL5865252 | 0.78 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2KMT2ATSHRL3MBTL1 | |
| SCHEMBL2925643 | 0.77 | WDR5 (0.46) | MAPTLMNASMN1; SMN2KMT2ACCR2 | |
| SCHEMBL5865539 | 0.77 | MAPK1 (0.50) | MAPTKMT2ACCR2TSHRL3MBTL1 | |
| SCHEMBL1495711 | 0.76 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2KMT2ATSHRL3MBTL1 | |
| SCHEMBL1495405 | 0.76 | KMT2A (0.62) | MAPTLMNASMN1; SMN2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091248-B2 | Treatment of adrenocortical hypersecretion and tumor growth | BRANDT INGVAR | 2006-08-15 | — | — | US | disclosed |
| US-20040242705-A1 | Novel treatment of adrenocortical hypersecretion and tumour growth | BRANDT INGVAR (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242705-A1 | Novel treatment of adrenocortical hypersecretion and tumour growth | NR3C2, NR5A1, NR3C1 | MAPT 4158/4885LMNA 4842/4885SMN1; SMN2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.